Unveiling the Role of Exarafenib in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes

Class II and class III BRAF-mutated cancers represent a significant clinical challenge, characterized by limited therapeutic options. Leveraging the GuardantINFORMTM database, which comprises genomic data from patients with advanced-stage solid tumors, we revealed a high number of patients harboring BRAF mutations in Non-Small Cell Lung Cancer (NSCLC). Exarafenib, a novel Type 2 pan-RAF inhibitor, demonstrates promise against all BRAF alterations by targeting both mutant monomers and dimers, irrespective of isoform. Our comprehensive investigation, utilizing both cellular and mouse tumor models, has confirmed exarafenib's robust anti-tumor activity in NSCLC. To further enhance its therapeutic potential, our study identified MEK inhibitors as a potent synergistic partner for exarafenib. Translating these findings to the clinical setting, we demonstrate exarafenib's significant efficacy in BRAF-mutated NSCLC patients. This study highlights exarafenib's potential to transform treatment paradigms for class II and III BRAF-mutated NSCLC, offering improved outcomes for this challenging patient cohort.

Ⅱ类与Ⅲ类BRAF突变型癌症是极具临床挑战性的疾病，其治疗选择极为有限。本研究依托收录晚期实体瘤患者基因组数据的GuardantINFORMTM数据库，发现非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）群体中存在大量BRAF突变阳性患者。依拉非尼（Exarafenib）作为新型2型泛RAF抑制剂，可通过靶向BRAF突变单体与二聚体覆盖所有BRAF变异类型，且不受蛋白亚型影响，展现出优异的抗肿瘤治疗潜力。本研究通过细胞与小鼠肿瘤模型开展的全面探究，证实依拉非尼在NSCLC中具有强劲的抗肿瘤活性。为进一步提升其治疗潜力，本研究发现MEK抑制剂可与依拉非尼产生强效协同作用。将上述研究成果转化至临床场景后，本研究证实依拉非尼对BRAF突变型NSCLC患者具有显著疗效。本研究凸显了依拉非尼有望革新Ⅱ类与Ⅲ类BRAF突变型NSCLC的治疗范式，为这一难治患者群体带来更优的治疗结局。